Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
Pharvaris said its pivotal CHAPTER-3 Phase 3 study of deucrictibant XR met its primary endpoint with statistically significant and clinically meaningful topline results in preventing hereditary angioedema attacks. The result strengthens the case for Pharvaris’s oral prophylaxis program, but the magnitude and full safety detail remain undisclosed in the announcement excerpt.
Pharvaris announced on Sept. 8 that CHAPTER-3, a pivotal Phase 3 study evaluating an extended-release tablet of deucrictibant for HAE attack prevention, produced statistically significant and clinically meaningful topline results. The company said the study met its primary endpoint, but the announcement excerpt does not include the effect size, attack-rate data, p-value, patient count or safety findings.
The study tests the prophylaxis use of deucrictibant XR, an oral bradykinin B2 receptor antagonist. Pharvaris is developing the drug for bradykinin-mediated angioedema, including hereditary angioedema and acquired angioedema due to C1 inhibitor deficiency; the result therefore addresses the central clinical question for its prevention program rather than an earlier-stage signal.
The direct commercial link is Pharvaris itself: a positive pivotal study could support the company’s regulatory and commercialization plans for an oral HAE prophylaxis product. The release does not identify a partner, disclose regulatory filing timing or provide comparative data against existing preventive therapies.
The evidence is positive but incomplete at the topline level. GlobeNewswire’s announcement excerpt does not state how large the treatment effect was or describe the safety profile, and those details will determine how much the result changes the product’s clinical and competitive positioning.
The next points to watch are Pharvaris’s full CHAPTER-3 dataset, including attack reduction, statistical details and adverse events, followed by any regulatory submission or agency interaction. No dated follow-up event is identified in the announcement excerpt.
The CHAPTER-3 readout moves the risk to the upside for PHVS, with the magnitude of the efficacy and safety profile still needed to validate the rerating.
The result improves the clinical and regulatory setup for PHVS because CHAPTER-3 is a pivotal Phase 3 prophylaxis study and the company describes the topline outcome as statistically significant and clinically meaningful. The read is not strong enough for a dated directional call yet: the announcement excerpt omits the treatment effect, patient count, p-value, safety findings and regulatory timetable.
A small or poorly differentiated treatment effect, an unfavorable safety profile, or a delayed regulatory path would weaken the positive read.
CoverageSource: GlobeNewswire · Published here TUE, SEP 8 · 6:50 AM ET · the only report in this recordHow this is decided →
Earlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
The strongest bull case is that a statistically significant and clinically meaningful result in a pivotal prophylaxis study gives Pharvaris a credible path for its oral deucrictibant XR program in HAE.
The bear case is that the excerpt supplies no effect size or safety detail, leaving open the possibility that the headline success is less commercially differentiated than it appears.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →